360 related articles for article (PubMed ID: 18600482)
1. Gene therapy for cystic fibrosis.
Mueller C; Flotte TR
Clin Rev Allergy Immunol; 2008 Dec; 35(3):164-78. PubMed ID: 18600482
[TBL] [Abstract][Full Text] [Related]
2. Recombinant adeno-associated virus vectors for cystic fibrosis gene therapy.
Flotte TR
Curr Opin Mol Ther; 2001 Oct; 3(5):497-502. PubMed ID: 11699895
[TBL] [Abstract][Full Text] [Related]
3. Vector-specific complementation profiles of two independent primary defects in cystic fibrosis airways.
Zhang Y; Jiang Q; Dudus L; Yankaskas JR; Engelhardt JF
Hum Gene Ther; 1998 Mar; 9(5):635-48. PubMed ID: 9551612
[TBL] [Abstract][Full Text] [Related]
4. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee TW; Southern KW
Cochrane Database Syst Rev; 2013 Nov; (11):CD005599. PubMed ID: 24282073
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy in cystic fibrosis.
Flotte TR; Laube BL
Chest; 2001 Sep; 120(3 Suppl):124S-131S. PubMed ID: 11555567
[TBL] [Abstract][Full Text] [Related]
6. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee TW; Southern KW
Cochrane Database Syst Rev; 2012 Oct; 10():CD005599. PubMed ID: 23076917
[TBL] [Abstract][Full Text] [Related]
7. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.
Wagner JA; Messner AH; Moran ML; Daifuku R; Kouyama K; Desch JK; Manley S; Norbash AM; Conrad CK; Friborg S; Reynolds T; Guggino WB; Moss RB; Carter BJ; Wine JJ; Flotte TR; Gardner P
Laryngoscope; 1999 Feb; 109(2 Pt 1):266-74. PubMed ID: 10890777
[TBL] [Abstract][Full Text] [Related]
8. A Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs.
Cooney AL; Thornell IM; Singh BK; Shah VS; Stoltz DA; McCray PB; Zabner J; Sinn PL
Am J Respir Cell Mol Biol; 2019 Dec; 61(6):747-754. PubMed ID: 31184507
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill.
Boucher RC; Knowles MR; Johnson LG; Olsen JC; Pickles R; Wilson JM; Engelhardt J; Yang Y; Grossman M
Hum Gene Ther; 1994 May; 5(5):615-39. PubMed ID: 7519885
[TBL] [Abstract][Full Text] [Related]
10. Toward cystic fibrosis gene therapy.
Wagner JA; Gardner P
Annu Rev Med; 1997; 48():203-16. PubMed ID: 9046956
[TBL] [Abstract][Full Text] [Related]
11. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
12. [Gene therapy in mucoviscidosis].
Schatz C; Pavirani A
Rev Pneumol Clin; 1995; 51(3):201-6. PubMed ID: 7569584
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia.
Granio O; Ashbourne Excoffon KJ; Henning P; Melin P; Norez C; Gonzalez G; Karp PH; Magnusson MK; Habib N; Lindholm L; Becq F; Boulanger P; Zabner J; Hong SS
Hum Gene Ther; 2010 Mar; 21(3):251-69. PubMed ID: 19788389
[TBL] [Abstract][Full Text] [Related]
14. Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis.
King NE; Suzuki S; Barillà C; Hawkins FJ; Randell SH; Reynolds SD; Stripp BR; Davis BR
Hum Gene Ther; 2020 Sep; 31(17-18):956-972. PubMed ID: 32741223
[TBL] [Abstract][Full Text] [Related]
15. Widespread airway distribution and short-term phenotypic correction of cystic fibrosis pigs following aerosol delivery of piggyBac/adenovirus.
Cooney AL; Singh BK; Loza LM; Thornell IM; Hippee CE; Powers LS; Ostedgaard LS; Meyerholz DK; Wohlford-Lenane C; Stoltz DA; B McCray P; Sinn PL
Nucleic Acids Res; 2018 Oct; 46(18):9591-9600. PubMed ID: 30165523
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector.
Sirninger J; Muller C; Braag S; Tang Q; Yue H; Detrisac C; Ferkol T; Guggino WB; Flotte TR
Hum Gene Ther; 2004 Sep; 15(9):832-41. PubMed ID: 15353038
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy for Cystic Fibrosis Paved the Way for the Use of Adeno-Associated Virus in Gene Therapy.
Guggino WB; Cebotaru L
Hum Gene Ther; 2020 May; 31(9-10):538-541. PubMed ID: 32283956
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors.
Mueller C; Strayer MS; Sirninger J; Braag S; Branco F; Louboutin JP; Flotte TR; Strayer DS
Gene Ther; 2010 Feb; 17(2):227-37. PubMed ID: 19890354
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.
Flotte TR; Zeitlin PL; Reynolds TC; Heald AE; Pedersen P; Beck S; Conrad CK; Brass-Ernst L; Humphries M; Sullivan K; Wetzel R; Taylor G; Carter BJ; Guggino WB
Hum Gene Ther; 2003 Jul; 14(11):1079-88. PubMed ID: 12885347
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Immunological Challenges to Helper-Dependent Adenoviral Vector-Mediated Long-Term
Cao H; Duan R; Hu J
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32443586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
